S. Schalm

Science · 2013–2014

A researcher in the Science corpus: 3 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from S. Schalm's perspective

Ordered by how strongly the researchers S. Schalm trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer (Nature)
  2. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. (New England Journal of Medicine)
  3. Ceritinib in ALK-rearranged non-small-cell lung cancer. (New England Journal of Medicine)
  4. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib (PLoS Medicine)
  5. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
  6. Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers (Nature Medicine)
  7. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
  8. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors (Cancer Discovery)
  9. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (New England Journal of Medicine)
  10. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions (Nature Reviews. Cancer)

Their papers